A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study.

作者:Prebet Thomas; Braun Thorsten; Rauzy Odile Beyne; Dreyfus Francois; Stamatoullas Aspasia; Wattel Eric; Ame Shanti; Raffoux Emmanuel; Delaunay Jacques; Salanoubat Celia; Mathieu Isabelle; Chermat Fatiha; Ades Lionel; Fenaux Pierre; Vey Norbert
来源:52nd Annual Meeting of the American-Society-of-Hematology (ASH), 2010-12-04 to 2010-12-07.
  • 出版日期2010-11-19